Management of HIV-Related Lung Disease and Cardiovascular Co-Morbidity (R34)

The summary for the Management of HIV-Related Lung Disease and Cardiovascular Co-Morbidity (R34) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Management of HIV-Related Lung Disease and Cardiovascular Co-Morbidity (R34): This FOA invites clinical trials planning grant (R34) applications to support the initial organization, protocol development, and necessary preliminary studies critical for the design of robust Phase II and III clinical trials in HIV-infected populations with lung disease alone or with cardiovascular co-morbidity. The focus of the clinical trials designed in this program will be on optimizing intervention strategies for HIV-related lung disease, with or without co-morbid cardiovascular disease, to reduce morbidity and mortality associated with these conditions.

Federal Grant Title:	Management of HIV-Related Lung Disease and Cardiovascular Co-Morbidity (R34)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HL-12-034
Type of Funding:	Grant
CFDA Numbers:	93.838
CFDA Descriptions:	Lung Diseases Research
Current Application Deadline:	Mar 15, 2012
Original Application Deadline:	Mar 15, 2012
Posted Date:	November 17th, 2011
Creation Date:	Nov 17, 2011
Archive Date:	Apr 15, 2012
Total Program Funding:	$2,000,000
Maximum Federal Grant Award:	$400,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Limited Competition: Physician Scientist Transition to Independence in Blood Science Resea...; • Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Data Coordi...; • Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Human Tissu...; • Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Research Centers (U01 Clin...; • Pathogenesis of Sars Lung Disease: in Vitro Studies and Animal Models; • Lung Response to Inhaled Highly Toxic Chemicals; • Protein Interactions Governing Membrane Transport in Pulmonary Health and Disease (R01)
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...